[Previous Months][Date Index][Thread Index][Join - Register][Login]
[Message Prev][Message Next][Thread Prev][Thread Next]

[IP] pain free glucose sensor deal



MiniMed Inc. Announces Joint Research Program with Lawrence Livermore
NationalLaboratory and Receipt of Advanced Technology Program Award


SYLMAR, Calif., Oct. 19 /PRNewswire/ -- MiniMed Inc.and the Department
of Energy's
Lawrence Livermore National Laboratory (LLNL) announced today a joint
research
program pursuant to a Cooperative Research and Development Agreement
(CRADA)
to develop glucose sensor technologies for the treatment of diabetes. 
MiniMed
also announced the receipt of a $2 million grant under the Advanced
Technology
Program (ATP) awarded by the National Institute of Standards and
Technology.
This grant will help fund a portion of MiniMed's activities under the
CRADA.
There's a lot of nothing in the following article, but it does hint that
MiniMed is getting serious about a painless, yet continuous, glucose
sensor in addition to the one we've all heard about that's inserted into
the abdomen - not exactly pain free.

Kasey



The ATP is a rigorously competitive program which provides cost-shared
awards
to industry for development of high- risk, enabling technologies with
broad
economic potential.  MiniMed was one of several award recipients
selected
among 167 proposals submitted in the ATP 1998 General Competition. 

Scientists at LLNL and MiniMed have been working for two years in early
stage
research to examine novel technologies for glucose sensing to assist in
the
management of diabetes.  Under the arrangement, each party contributes
scientific, financial and other technical resources in the development
of
technology intended to provide continuous glucose readings through a
convenient and pain free device.  The ATP has awarded MiniMed $2 million
over
a three-year term towards MiniMed's share of the investment in the
program. 

Alfred E. Mann, Chairman and Chief Executive Officer of MiniMed, stated,
"We
are committed to providing the most advanced technologies to prevent the
awful
consequences of the dreaded disease of diabetes and we have long
recognized
the need for continuous monitoring of glucose levels in diabetics. As a
result, MiniMed has been exploring a number of novel alternate sensing
approaches and has begun this collaborative arrangement with Lawrence
Livermore National Laboratories.  This arrangement makes it possible for
us to
work with some of the most qualified scientific and technical experts in
the
country." 

Terrance H. Gregg, President and Chief Operating Officer of MiniMed,
added,
"We are pleased with the progress of our program with Lawrence Livermore
and
are hopeful that this effort will contribute to our mission of improving
the
lives of people with diabetes.  The technology being developed in this
collaboration is a novel approach that may offer additional benefits
over
current systems for the measurement of glucose." 

Dr. Steven Lane, Project Leader for the Lawrence Livermore National
Laboratory's Scientific Team, stated, "Members of the scientific team
assigned
to this project have spent over a decade at LLNL developing highly
sensitive
measurement instruments for defense related projects such as laser
fusion.  We
are grateful for the opportunity to apply our experience to a project
that may
have a significant impact on an important and urgent health care
problem." 

MiniMed is the world leader in infusion systems for the delivery of
insulin
for the treatment of diabetes.  The Company's vision is to combine
insulin
delivery pumps with glucose sensors to create an artificial pancreas. In
December 1997, MiniMed announced the submission of an application for
regulatory clearance from the United States Food and Drug Administration
to
produce and market a minimally invasive continuous subcutaneous glucose
sensor. 

MiniMed continues to explore alternative glucose sensing technologies to
better serve a varied cross section of the diabetes patient population. 
The
current worldwide market for glucose meters and test strips is estimated
to be
approximately $3 billion annually. 

Under the CRADA arrangement, LLNL has established a multidisciplinary
team
which includes experts in chemical synthesis, bioengineering,
optoelectronics,
chemical sensors, and computer modeling.  The contribution of LLNL is
part of
a larger effort to develop sensors for other defense, environmental and
biomedical applications, and efforts at the DOE to apply the benefits of
scientific advances achieved in advancing National Security to the field
of
medicine. 

Lawrence Livermore National Laboratory is a U.S. Department of Energy
facility
managed by the University of California.  National security is the
laboratory's defining mission, with a broad focus that includes research
in
energy, the environment, biomedicine and fundamental science and
technology.
The laboratory also serves as a resource to government and a partner to
industry and academia. 

MiniMed Inc. designs, develops, manufactures and markets advanced
infusion
systems with a primary emphasis on the intensive management of
diabetes.  The
Company's products include external pumps and related disposables, as
well as
the distribution of an implantable insulin pump, which is currently
approved
for sale in the European Community and has not yet been cleared for
marketing
in the U.S.  The Company also distributes other diabetes supplies and
pharmaceutical products.  The Company has submitted an application for
marketing clearance for a system designed to continuously monitor
glucose
levels, is preparing to introduce other glucose monitoring products, and
is
developing new infusion systems to deliver compounds designed to treat a
variety of medical conditions. 

Any statements made by MiniMed in this press release that are
forward-looking,
including statements relating to the ability to complete successfully
the
development of sensor technology, the ability to develop a convenient
and pain
free device to provide continuous monitoring, the receipt of all $2
million of
ATP funding, the development of a technology that may offer additional
benefits in the measurement of glucose for a broad range of
applications, the
commercial viability of the sensor, the ability to obtain regulatory
approval
with respect to any sensor products, the ability of MiniMed to combine
any
sensor product with any insulin pump to create an "artificial pancreas,"
the
ability of MiniMed to manufacture any sensor products, the commercial
market
for MiniMed's glucose sensor products and the impact of commercial
introduction of such products on MiniMed's insulin infusion pump
business are
made pursuant to the Safe Harbor provisions of the Private Securities
Reform
Act of 1995.  Investors are cautioned that forward- looking statements
involve
risks and uncertainties which may affect MiniMed's business and
prospects,
including changes in economic and market conditions, acceptance of
MiniMed's
products by the health care and reimbursement communities, health care
legislation, new developments in diabetes therapy, administration and
regulatory approval and related considerations, and other factors
discussed in
the Company's filings with the Securities and Exchange Commission. 

SOURCE  MiniMed Inc. 

CO:  MiniMed Inc.; Lawrence Livermore National Laboratory 

10/19/98 07:32 EDT http://www.prnewswire.com

Insulin-Pumpers website http://www.bizsystems.com/Diabetes/